Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia

A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation

(2021) Nelli Bejanyan et al.   Blood Advances

HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis

(2021) Mahasweta Gooptu et al.   BLOOD

Coadministration of letermovir and sirolimus in allogeneic hematopoietic cell transplant recipients

(2021) Elisabetta Xue et al.   BONE MARROW TRANSPLANTATION

Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor–Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies

(2021) Leo Luznik et al.   JOURNAL OF CLINICAL ONCOLOGY

Haploidentical donor transplant is associated with secondary poor graft function after allogeneic stem cell transplantation: A single‐center retrospective study

(2021) Wei‐Ran Lv et al.   Cancer Medicine

Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients

(2020) Alexandros Spyridonidis et al.   BONE MARROW TRANSPLANTATION

Uniform graft-versus-host disease prophylaxis with posttransplant cyclophosphamide, sirolimus, and mycophenolate mofetil following hematopoietic stem cell transplantation from haploidentical, matched sibling and unrelated donors

(2020) Juan Montoro et al.   BONE MARROW TRANSPLANTATION

Post-transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT

(2020) Jaime Sanz et al.   Journal of Hematology & Oncology

Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia

(2020) Francesca Lorentino et al.   LEUKEMIA

Post-transplant cyclophosphamide versus antithymocyte globulin in patients with acute myeloid leukemia in first complete remission undergoing allogeneic stem cell transplantation from 10/10 HLA-matched unrelated donors

(2020) Eolia Brissot et al.   Journal of Hematology & Oncology

Conditioning Intensity, Pre-Transplant Flow Cytometric Measurable Residual Disease, and Outcome in Adults with Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation

(2020) Linde M. Morsink et al.   Cancers

Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T cell dysfunction and suppression

(2019) Lucas P. Wachsmuth et al.   JOURNAL OF CLINICAL INVESTIGATION

Graft Failure after Haploidentical Hematopoietic Stem Cell Transplantation

(2019) Cindy Lynn Hickey et al.   BLOOD

Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease

(2019) Christopher S. Hourigan et al.   JOURNAL OF CLINICAL ONCOLOGY

Haploidentical transplantation might have superior graft-versus-leukemia effect than HLA-matched sibling transplantation for high-risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study

(2019) Sijian Yu et al.   LEUKEMIA

Treosulfan or busulfan plus fludarabine as conditioning treatment before allogeneic haemopoietic stem cell transplantation for older patients with acute myeloid leukaemia or myelodysplastic syndrome (MC-FludT.14/L): a randomised, non-inferiority, phase 3 trial

(2019) Dietrich Wilhelm Beelen et al.   Lancet Haematology

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

(2018) Gerrit J. Schuurhuis et al.   BLOOD

CD3+ graft cell count influence on chronic GVHD in haploidentical allogeneic transplantation using post-transplant cyclophosphamide

(2018) A Mussetti et al.   BONE MARROW TRANSPLANTATION

Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

(2018) Dalila Salvatore et al.   HAEMATOLOGICA

Post-transplant cyclophosphamide for graft-versus-host disease prophylaxis in HLA matched sibling or matched unrelated donor transplant for patients with acute leukemia, on behalf of ALWP-EBMT

(2018) Annalisa Ruggeri et al.   Journal of Hematology & Oncology

Outcomes of hematopoietic stem cell transplantation from unmanipulated haploidentical versus matched sibling donor in patients with acute myeloid leukemia in first complete remission with intermediate or high-risk cytogenetics: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

(2018) Dalila Salvatore et al.   HAEMATOLOGICA

ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients

(2017) Simone Cesaro et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2017) Bart L. Scott et al.   JOURNAL OF CLINICAL ONCOLOGY

Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis

(2017) Ying-Jun Chang et al.   Journal of Hematology & Oncology

Posttransplantation cyclophosphamide and sirolimus for prevention of GVHD after HLA-matched PBSC transplantation

(2016) R. Greco et al.   BLOOD

Posttransplantation cyclophosphamide for prevention of graft-versus-host disease after HLA-matched mobilized blood cell transplantation

(2016) M. Mielcarek et al.   BLOOD

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel

(2016) Hartmut Döhner et al.   BLOOD

Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation

(2016) M Mohty et al.   BONE MARROW TRANSPLANTATION

Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.

(2016) Per Ljungman et al.   CLINICAL INFECTIOUS DISEASES

Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus -host disease prophylaxis in haploidentical transplant

(2016) Annalisa Ruggeri et al.   HAEMATOLOGICA

Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

(2016) J. Styczynski et al.   HAEMATOLOGICA

Post-transplant cyclophosphamide versus anti-thymocyte globulin as graft- versus -host disease prophylaxis in haploidentical transplant

(2016) Annalisa Ruggeri et al.   HAEMATOLOGICA

Management of Epstein-Barr Virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: Sixth European Conference on Infections in Leukemia (ECIL-6) guidelines

(2016) J. Styczynski et al.   HAEMATOLOGICA

HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning

(2015) Junichi Sugita et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells

(2015) Nicoletta Cieri et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

(2015) S. O. Ciurea et al.   BLOOD

Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial

(2015) Alessandro Rambaldi et al.   LANCET ONCOLOGY

Calcineurin Inhibitor–Free Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide and Brief-Course Sirolimus Following Reduced-Intensity Peripheral Blood Stem Cell Transplantation

(2014) Scott R. Solomon et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS

(2014) C. G. Kanakry et al.   BLOOD

Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation

(2014) P. Armand et al.   BLOOD

Sirolimus-based graft-versus-host disease prophylaxis promotes the in vivo expansion of regulatory T cells and permits peripheral blood stem cell transplantation from haploidentical donors

(2014) J Peccatori et al.   LEUKEMIA

T-Cell–Replete HLA-Haploidentical Hematopoietic Transplantation for Hematologic Malignancies Using Post-Transplantation Cyclophosphamide Results in Outcomes Equivalent to Those of Contemporaneous HLA-Matched Related and Unrelated Donor Transplantation

(2013) Asad Bashey et al.   JOURNAL OF CLINICAL ONCOLOGY

Haploidentical Transplantation Using T Cell Replete Peripheral Blood Stem Cells and Myeloablative Conditioning in Patients with High-Risk Hematologic Malignancies Who Lack Conventional Donors is Well Tolerated and Produces Excellent Relapse-Free Survival: Results of a Prospective Phase II Trial

(2012) Scott R. Solomon et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A disease risk index for patients undergoing allogeneic stem cell transplantation

(2012) P. Armand et al.   BLOOD

Graft failure in the modern era of allogeneic hematopoietic SCT

(2012) R Olsson et al.   BONE MARROW TRANSPLANTATION

Reduced-intensity conditioning versus standard conditioning before allogeneic haemopoietic cell transplantation in patients with acute myeloid leukaemia in first complete remission: a prospective, open-label randomised phase 3 trial

(2012) Martin Bornhäuser et al.   LANCET ONCOLOGY

Defining the Intensity of Conditioning Regimens: Working Definitions

(2009) Andrea Bacigalupo et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Reduced Intensity Conditioning Compared With Myeloablative Conditioning Using Unrelated Donor Transplants in Patients With Acute Myeloid Leukemia

(2009) Olle Ringdén et al.   JOURNAL OF CLINICAL ONCOLOGY

HLA-Haploidentical Bone Marrow Transplantation for Hematologic Malignancies Using Nonmyeloablative Conditioning and High-Dose, Posttransplantation Cyclophosphamide

(2008) Leo Luznik et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group

(2008) Ben De Pauw et al.   CLINICAL INFECTIOUS DISEASES